Delivery Order SPE2DR25D2005-SPE2DR26FF0J5
- Not listed
- AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, was awarded a delivery order by the Defense Logistics Agency (DLA) on December 22, 2025, for the supply of Hyzaar 100-12.5 mg tablets (30-count packaging). This competitively awarded, non-set-aside contract carries a ceiling value of $1,972.32 and is structured as a firm fixed price delivery order with an ultimate completion date of December 23, 2025. The place of performance is located in Conshohocken, Pennsylvania,...
- The Defense Logistics Agency (DLA) awarded a $7,941.41 delivery order to AmerisourceBergen Drug Corp for HYZAAR 100-12.5 tablets (90-count units) on July 30, 2025, with completion targeted for July 31, 2025. This competitively awarded, non-set-aside contract utilizes firm fixed pricing and is being fulfilled from AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The delivery order represents a pharmaceutical supply requirement supporting federal medical procurement...
- The Defense Logistics Agency awarded a $15,164.14 delivery order to AmerisourceBergen Drug Corp on August 27, 2025, for the supply of Hyzaar 50-12.5 mg tablets (30-count units). This is a firm fixed-price, competitively awarded contract with no set-aside designation and an ultimate completion date of August 28, 2025. The contract is being performed from AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's larger...
- The Defense Logistics Agency awarded a delivery order valued at $12,435.70 to AmerisourceBergen Drug Corp on August 25, 2025, for the supply of HYZAAR 50-12.5 mg tablets (30-count packages). This competitively awarded, firm fixed-price delivery order is scheduled for completion by August 26, 2025, with performance taking place at the vendor's corporate office location in Conshohocken, Pennsylvania. The contract represents a non-set-aside procurement, reflecting the vendor's demonstrated...
- The Defense Logistics Agency awarded a $2,237.52 delivery order to AmerisourceBergen Drug Corp for HYZAAR 50-12.5 tablets (30-count packages) on November 13, 2025, with an ultimate completion date of November 14, 2025. This non-set-aside contract utilizes firm fixed pricing and represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at $999,999,999.00 and running through December 2026. The work will be performed...
- The Defense Logistics Agency awarded a $2,297.90 firm fixed-price delivery order to AmerisourceBergen Drug Corp for 30-count tablets of Hyzaar 50-12.5, a combination antihypertensive medication. This non-set-aside competitive award was issued on September 3, 2025, with an ultimate completion date of September 4, 2025, and will be performed at the contractor's corporate office location in Conshohocken, Pennsylvania. The delivery order represents a child contract under AmerisourceBergen's larger...
- The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp for supply of HYZAAR 50-12.5 tablets in quantities of 30 units, with a contract ceiling value of $2,027.66. This competitively awarded, non-set-aside delivery order utilizes firm fixed pricing and carries an ultimate completion date of November 28, 2025. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, is performing the work at its corporate...
- This federal contract award is for the delivery of Hyzaar 100-25 tablets to the Defense Logistics Agency (DLA). The $7,654.47 firm fixed-price delivery order was awarded to AmerisourceBergen Drug Corp, a major pharmaceutical distributor, on February 1, 2022 with a completion date of February 2, 2022. AmerisourceBergen Drug Corp is a subsidiary of the parent company Cencora, Inc. and is registered in the System for Award Management (SAM.gov) as a for-profit organization. The contract does not...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on October 28, 2025, for the supply of HYZAAR 50-12.5 mg tablets (30-count units) valued at $1,549.20. This is a firm fixed-price delivery order with no set-aside designation, indicating it was competitively awarded. The order is scheduled for completion by October 29, 2025, and will be performed at AmerisourceBergen's facility in Conshohocken, Pennsylvania, where the company maintains its corporate...
- The Defense Logistics Agency awarded a $1,474.23 delivery order to AmerisourceBergen Drug Corp for HYZAAR 100-25 tablets (90-count supply) on December 18, 2025, with completion scheduled for December 19, 2025. This firm fixed-price contract represents a non-set-aside competitive award to the prime contractor, with performance occurring at AmerisourceBergen's facility in Conshohocken, Pennsylvania. HYZAAR is a combination antihypertensive medication used in treating high blood pressure,...
- SPE2DR25D2005Indefinite Delivery Contract
- SPE2DR25D2005-SPE2DR26FF0J5Delivery Order
The Defense Logistics Agency (DLA) awarded a delivery order valued at $1,416.58 to AmerSourceBergen Drug Corp on January 8, 2026, for the supply of Hyzaar 100-25 tablets (30-count packages). This competitively awarded, firm fixed-price contract involves no set-aside designation and specifies a completion date of January 9, 2026. The pharmaceutical product will be delivered to AmerSourceBergen's corporate office location in Conshohocken, Pennsylvania, where the company maintains its primary operations as a major pharmaceutical distributor and healthcare solutions provider. This delivery order represents a task order under AmerSourceBergen's parent company Cencora, Inc.'s larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at up to $999,999,999.00 through December 2031. That comprehensive IDC vehicle enables the supply of a broad portfolio of pharmaceutical products and medical supplies—including specialty medications, brand-name and generic drugs, vaccines, and medical devices—to support military healthcare programs globally. The arrangement allows DLA to efficiently procure essential pharmaceuticals across multiple therapeutic domains to serve Defense Health Agency facilities, the U.S. Coast Guard, and other federal medical institutions.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $1.4k | 1/7/26 |